$ADVM
Adverum Biotechnologies, Inc. Stock $advm

$advm Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000162828020008534 Filed on May 28, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$0.00	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.040M	$5.580M
YoY Change	62.01%	3.91%
% of Gross Profit
Research & Development	$14.75M	$10.13M
YoY Change	45.6%	-20.81%
% of Gross Profit
Depreciation & Amortization	$600.0K	$430.0K
YoY Change	39.53%	-6.52%
% of Gross Profit
Operating Expenses	$23.79M	$15.71M
YoY Change	51.47%	-13.52%
Operating Profit	-$23.79M	-$15.71M
YoY Change	51.47%	-12.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$885.0K	$1.218M
YoY Change	-27.34%	63.27%
Pretax Income	-$22.91M	-$14.49M
YoY Change	58.11%	-15.76%
Income Tax
% Of Pretax Income
Net Earnings	-$22.91M	-$14.49M
YoY Change	58.09%	-15.76%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$310.4K	-$229.5K
COMMON SHARES
Basic Shares Outstanding		63.20M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$297.1M	$189.5M
YoY Change	56.78%	-23.28%
Cash & Equivalents	$130.2M	$145.1M
Short-Term Investments	$166.9M	$45.40M
Other Short-Term Assets	$3.400M	$3.600M
YoY Change	-5.56%	63.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$300.4M	$193.1M
YoY Change	55.59%	-22.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.73M	$26.70M
YoY Change	0.1%	853.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$19.00K	$1.200M
YoY Change	-98.42%	1100.0%
Total Long-Term Assets	$48.15M	$27.90M
YoY Change	72.58%	248.75%
TOTAL ASSETS
Total Short-Term Assets	$300.4M	$193.1M
Total Long-Term Assets	$48.15M	$27.90M
Total Assets	$348.6M	$221.0M
YoY Change	57.74%	-14.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.663M	$1.800M
YoY Change	159.06%	157.14%
Accrued Expenses	$12.10M	$8.900M
YoY Change	35.96%	23.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.77M	$10.60M
YoY Change	58.18%	14.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$126.0K	$216.0K
YoY Change	-41.67%	-46.53%
Total Long-Term Liabilities	$126.0K	$216.0K
YoY Change	-41.67%	-46.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.77M	$10.60M
Total Long-Term Liabilities	$126.0K	$216.0K
Total Liabilities	$44.65M	$32.90M
YoY Change	35.7%	239.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$407.9M
YoY Change
Common Stock	$712.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$304.0M	$188.1M
YoY Change
Total Liabilities & Shareholders Equity	$348.6M	$221.0M
YoY Change	57.74%	-14.07%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$22.91M	-$14.49M
YoY Change	58.09%	-15.76%
Depreciation, Depletion And Amortization	$600.0K	$430.0K
YoY Change	39.53%	-6.52%
Cash From Operating Activities	-$13.62M	-$13.22M
YoY Change	3.02%	1.79%
INVESTING ACTIVITIES
Capital Expenditures	$4.210M	$2.186M
YoY Change	92.59%	912.04%
Acquisitions
YoY Change
Other Investing Activities	-$66.53M	$4.930M
YoY Change	-1449.49%	-80.74%
Cash From Investing Activities	-$70.74M	$2.745M
YoY Change	-2677.16%	-89.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$148.6M	-$370.0K
YoY Change	-40268.65%	-100.53%
NET CHANGE
Cash From Operating Activities	-$13.62M	-$13.22M
Cash From Investing Activities	-$70.74M	$2.745M
Cash From Financing Activities	$148.6M	-$370.0K
Net Change In Cash	$64.27M	-$10.84M
YoY Change	-692.74%	-113.19%
FREE CASH FLOW
Cash From Operating Activities	-$13.62M	-$13.22M
Capital Expenditures	$4.210M	$2.186M
Free Cash Flow	-$17.83M	-$15.40M
YoY Change	15.73%	16.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001501756
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-36579
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Adverum Biotechnologies, Inc.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5258327
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 Saginaw Drive,
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
CY2020Q1	dei	City Area Code CityAreaCode	650
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	656-9323
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2020Q1	dei	Trading Symbol TradingSymbol	ADVM
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	80295560	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130162000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65897000	USD
CY2020Q1	us-gaap	Short Term Investments ShortTermInvestments	166904000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	100138000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3382000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9835000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	300448000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	175870000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4103000	USD
CY2020Q1	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	8079000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20406000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20963000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26727000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24884000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	999000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	999000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11000	USD
CY2020Q1	us-gaap	Assets Assets	348599000	USD
CY2019Q4	us-gaap	Assets Assets	222727000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4663000	USD
CY2019Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	11271000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4025000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4034000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16767000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19408000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27753000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28214000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	126000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	148000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	44646000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	47770000	USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	712713000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	560704000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-833000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-725000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-22906000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-407935000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5576000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	23791000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	15707000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-385029000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	303953000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	174957000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	348599000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	222727000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14751000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10131000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9040000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23791000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15707000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	885000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1218000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-22906000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-14489000	USD
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-54000	USD
CY2019Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-54000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	42000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23014000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14444000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	73797000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63125000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	174957000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3409000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	332000	USD
CY2020Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10925000	shares
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140873000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9650000	USD
CY2020Q1	advm	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod	7000	shares
CY2020Q1	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	1922000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-54000	USD
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-54000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-22906000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	303953000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	201167000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1762000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	162000	USD
CY2019Q1	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	0	USD
CY2019Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	504000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	42000	USD
CY2019Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-14489000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	188143000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-14489000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	599000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	426000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3409000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1762000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	179000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	129000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	48000	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-40000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6345000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	91000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	18000	USD
CY2020Q1	advm	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-557000	USD
CY2019Q1	advm	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-539000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2514000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-136000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3429000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2363000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2186000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70743000	USD
CY2019Q1	advm	Proceeds From Offerings Of Common Stock Net Of Issuance Costs ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts	0	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9650000	USD
CY2020Q1	advm	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-470000	USD
CY2019Q1	advm	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	1242000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13616000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13217000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	127733000	USD
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	22454000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	61200000	USD
CY2019Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	27385000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4210000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2745000	USD
CY2020Q1	advm	Proceeds From Offerings Of Common Stock Net Of Issuance Costs ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts	140923000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	162000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66896000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145106000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	119540000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	166940000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1922000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	504000	USD
CY2020Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	27000	USD
CY2019Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	28000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	148624000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-370000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	64265000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10842000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	155948000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131161000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3474000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	413000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-407900000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div>
CY2020Q1	advm	Cash And Cash Equivalent Amortized Cost CashAndCashEquivalentAmortizedCost	119540000	USD
CY2020Q1	advm	Cash And Cash Equivalent Gross Unrealized Gain CashAndCashEquivalentGrossUnrealizedGain	15000	USD
CY2020Q1	advm	Cash And Cash Equivalent Gross Unrealized Loss CashAndCashEquivalentGrossUnrealizedLoss	15000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	103000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	139000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	166904000	USD
CY2019Q4	advm	Cash And Cash Equivalent Amortized Cost CashAndCashEquivalentAmortizedCost	51391000	USD
CY2019Q4	advm	Cash And Cash Equivalent Gross Unrealized Gain CashAndCashEquivalentGrossUnrealizedGain	0	USD
CY2019Q4	advm	Cash And Cash Equivalent Gross Unrealized Loss CashAndCashEquivalentGrossUnrealizedLoss	3000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	51388000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	100117000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	28000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	100138000	USD
CY2020Q1	advm	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Two Years DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears	20300000	USD
CY2020Q1	advm	Other Than Temporary Impaired Investments Available For Sale Securities OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities	0	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	600000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7992000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26727000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24884000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	35318000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	32876000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8591000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
CY2020Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2299000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4055000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	207000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.05
CY2020Q1	advm	Accrued Preclinical Clinical And Development Process Costs AccruedPreclinicalClinicalAndDevelopmentProcessCosts	1823000	USD
CY2019Q4	advm	Accrued Preclinical Clinical And Development Process Costs AccruedPreclinicalClinicalAndDevelopmentProcessCosts	1973000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1466000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2607000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2491000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2636000	USD
CY2020Q1	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	8079000	USD
CY2019Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	11271000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8995000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.19
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1594000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.15
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9072000	shares
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1310000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.37
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1762000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.41
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2785000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.89
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3409000	USD
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9932000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9920000	shares

Files In Submission

Name	View Source	Status
0001628280-20-008534-index-headers.html	Edgar Link	pending
0001628280-20-008534-index.html	Edgar Link	pending
0001628280-20-008534.txt	Edgar Link	pending
0001628280-20-008534-xbrl.zip	Edgar Link	pending
advm-20200331.htm	Edgar Link	pending
advm-20200331.xsd	Edgar Link	pending
advm-20200331xex101.htm	Edgar Link	pending
advm-20200331xex102.htm	Edgar Link	pending
advm-20200331xex103.htm	Edgar Link	pending
advm-20200331xex311.htm	Edgar Link	pending
advm-20200331xex312.htm	Edgar Link	pending
advm-20200331xex321.htm	Edgar Link	pending
advm-20200331xex322.htm	Edgar Link	pending
advm-20200331_cal.xml	Edgar Link	unprocessable
advm-20200331_def.xml	Edgar Link	unprocessable
advm-20200331_htm.xml	Edgar Link	completed
advm-20200331_lab.xml	Edgar Link	unprocessable
advm-20200331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image01.jpg	Edgar Link	pending
image11.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADVM
Adverum Biotechnologies, Inc. Stock $advm

2020 Q1 Form 10-Q Financial Statement

#000162828020008534 Filed on May 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM Adverum Biotechnologies, Inc. Stock $advm

2020 Q1 Form 10-Q Financial Statement

#000162828020008534 Filed on May 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM
Adverum Biotechnologies, Inc. Stock $advm